Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
4/30/2010 11:58:16 AM
FREISING-WEIHENSTEPHAN, Germany, April 30, 2010 /PRNewswire/ -- Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin(R) compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model. The results provide an indication that an Anticalin approach to antagonizing the c-Met pathway may be of significant therapeutic value in treating cancer. A broad body of research has shown that c-Met plays a role in several mechanisms by which cancer cells proliferate and escape programmed cell death.